Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo. The US regulator says Retevmo (selpercatinib, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results